GRF(1-29) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Vasculitis a disorder where blood vessels are destroyed by inflammation. Can be life-threatening if it affects the right blood vessels. Galactorrhoea (lactation that is not associated with pregnancy or breast feeding) Delayed micturition (that is, delays in urination from when a conscious effort to urinate is made) Hyperthermia (elevation of body temperature; its seriousness depends on the extent of the hyperthermia) Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) this is basically when the body's level of the hormone, antidiuretic hormone, which regulates the conservation of water and the restriction of blood vessels, is elevated. This is potentially fatal as it can cause electrolyte abnormalities including hyponatraemia (low blood sodium), hypokalaemia (low blood potassium) and hypocalcaemia (low blood calcium) which can be life-threatening. Agranulocytosis a drop in white blood cell counts. The white blood cells are the cells of the immune system that fight off foreign invaders. Hence agranulocytosis leaves an individual open to life-threatening infections. Leukopaenia the same as agranulocytosis but less severe. Neuroleptic malignant syndrome (a potentially fatal reaction to antidopaminergic agents, most often antipsychotics. It is characterised by hyperthermia, diarrhoea, tachycardia, mental status changes [e.g. confusion], rigidity, extrapyramidal side effects) Tardive dyskinesia a most often irreversible neurologic reaction to antidopaminergic treatment, characterised by involuntary movements of facial muscles, tongue, lips, and other muscles.
Serve as a think tank to the government on the subject of cold-chain. NCCD engages with its members to translate industry needs into policy recommendation. Provide an enabling environment for cold chain sector and facilitate private investment for cold-chain infrastructure. Direction setting to narrow the gap in the supply and value chain including storage, specialised transport and operational or business processes. Address the concerns on standards and protocols related to cold-chain testing, verification, certification and accreditation. Assist in developing and promoting new and energy efficient technologies and their adaption in India. Capacity building and training activities to reduce the gap in skilled human resources required for cold-chain sector. Recommend guidelines to minimise environment impact and promote sustainability in the cold-chain. Awareness programs on best practices for perishable product handling, indigenised for specific requirements and conditions. In India, while almost 15% of fruits and vegetables have access to cold storage capacity, less than 5% of such goods are precooled or get transported in the cold-chain. This results in most of the fresh produce being subject to harsh climatic conditions, incurring gross loss of perishable food items. Similar lack of cold-chain in the pharmaceutical sector witnesses increased risk and loss of medical products. Lack of appropriate integrated infrastructure in this sector also increases risk to frozen foods shipments.
Furikake (振り掛け, ふりかけ, 振掛け, 振掛) is a dry Japanese condiment sprinkled on top of cooked rice, or used as an ingredient in onigiri. It typically consists of a mixture of dried fish or freeze-dried eggs, sesame seeds, dried seaweed flakes, sugar, and salt. Other ingredients, such as katsuobushi (sometimes indicated on the package as bonito), okaka (bonito flakes moistened with soy sauce and dried again), freeze-dried salmon particles, shiso, egg, powdered miso, or vegetables, are often added. Furikake is often brightly colored and flaky. It can have a slight fish or seafood flavoring and may be spicy or sweet. It can be used in Japanese cooking for pickling and for rice balls (onigiri).
Sources: en.wikipedia.org
=== Agriculture === Within a temperature regulated bath, seeds are rested between moisturized blotting paper as a germination device. This method is typically used in seed germinators, which create balanced conditions of humidity and temperature.
In the 19th century, in Bielefeld, Germany, epileptic patients were given the prescription to spend time each day taking care of cats and dogs. The contact with the animals was found to reduce the occurrence of seizures. As early as the 1920s, people were starting to utilize the human–animal bond not just for healing, but also granting independence through service animals. In 1929, The Seeing Eye Inc. school formed to train guide dogs for the blind in the United States, inspired by dogs being trained to guide World War I veterans in Europe. Furthermore, the idea is that the human-animal bond can provide health benefits to humans as the animals "appeal to fundamental human needs for companionship, comfort, and security..." In 1980, a team of scientists at the University of Pennsylvania found that human to animal contact was found to reduce the physiological characteristics of stress; specifically, blood pressure, heart rate, respiratory rate, anxiety, and tension were all found to correlate inversely with human–pet bonding. In some cases, despite its benefits, the human–animal bond can be used for harmful purposes. The 1990s saw an increase in social and scientific awareness of the use of companion animals as a tool for domestic violence. A 1997 study found that 80% of shelters reported women staying with them had experienced their abuser threatening or harming companion animals as a form of abuse. A 2003 study by the U.S.
=== Impact of demise === The impact of the demise of USAID on global health is wide reaching. A study published in The Lancet on June 30, 2025, estimated that funding cuts and the abolition of the agency could result in at least 14 million preventable deaths by 2030, 4.5 million of which could be among children under 5 years old. The study concluded that the discontinuation of PEPFAR alone could cause as many as 10.75 million new HIV infections and as many as 2.93 million deaths related to HIV. The study warned that for low and middle income countries, "the resulting shock would be similar in scale to a global pandemic or a major armed conflict." Another study published in March 2025 concluded that the suspension of PEPFAR could result in HIV-related deaths surging to as high as 630,000 per year. Christine Stegling, deputy executive director at UNAIDS, estimated that there could be a 400% increase in AIDS-related deaths around the world if PEPFAR was not formally reauthorized for USAID funding, which represents around 6.3 million AIDS-related deaths within four years. In 2024, PEPFAR funds accounted for 14% of the entire health budget of Zimbabwe. In March 2025, experts from the Center for Global Development estimated that before the freeze, USAID programs annually prevented approximately 1,650,000 deaths from HIV/AIDS, 500,000 deaths from lack of vaccines, 310,000 deaths from tuberculosis and 290,000 deaths from malaria. USAID-funded breast feeding programs to reduce malnutrition in Nepal were brought to a halt following the aid freeze on January 20, 2025.
== Veterinary uses == Phenobarbital is one of the first-line drugs of choice to treat epilepsy in dogs, as well as cats. It is also used to treat feline hyperesthesia syndrome in cats when anti-obsessional therapies prove ineffective. It may also be used to treat seizures in horses when benzodiazepine treatment has failed or is contraindicated.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.